Patent ID: 11903927
Assignee: SCANDION ONCOLOGY A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 7:
8. The method according to claim 1, wherein the VRAC modulator is a compound of general formula I, or a pharmaceutically acceptable salt thereof
wherein R2 represents tetrazolyl; and
R3, R4, R5, R6, R12, R13, R14, R15, and R16 independently of each other represent hydrogen, halo, trifluoromethyl, nitro, alkyl, alkylcarbonyl, —NRaRb, —NRa—CO—Rb, phenyl or heteroaryl;
which phenyl is optionally substituted with halo, trifluoromethyl, nitro, —CO—NHRc, —CO—O—Rc or —CO—NR′R″;
wherein Rc is hydrogen, alkyl, or phenyl;
R′ and R″ independently of each other are hydrogen or alkyl; or
R′ and R″ together with the nitrogen to which they are attached form a 5- to 7-membered heterocyclic ring, which ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen double bond;
and which heterocyclic ring may optionally be substituted with alkyl;
Ra and Rb independently of each other are hydrogen or alkyl; or
R15 and R16, or R14 and R15 together with the phenyl ring to which they are attached form a naphthyl ring or an indanyl ring; and R3, R4, R5, R6, R12 and R13 and the remaining one of R14, R15 and R16 are as defined above.